Where progressive supranuclear palsy treatment is heading
Progressive supranuclear palsy · Updated Nov 14, 2026
Progressive supranuclear palsy (PSP) is a brain disease in which the tau protein builds up and damages areas that control balance, eye movement, speech, swallowing and thinking. It is often first mistaken for Parkinson disease; roughly 20,000 Americans have it, with a few thousand diagnosed each year, usually in their 60s. There is no approved treatment to slow it, and Parkinson drugs help little. Several drugs have failed, but a tau-lowering antisense drug is now in phase 3 and a new platform trial tests several drugs at once.
- 57studies open or running
- 1phase 3 trials
- 377papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
Anti-tau antibodies reach their targetHappened 80.41% less free tau
Bepranemab cut free tau in spinal fluid by 80.41% and was well tolerated.
80.41%: reduction in free tau in spinal fluid.
Setbacks for other approachesHappened
AMX0035 showed no benefit and its trial was stopped; brain stimulation did not help symptoms.
Early signals from a progranulin drugHappened
AZP2006 was safe, with trends toward slower progression in a small trial.
-
6 months
by May 2027
An O-GlcNAcase inhibitorLikely
Ferrer's FNP-223 PROSPER trial (241 people), testing a pill meant to stop tau clumping, finishes November 2026.
-
12 months
by Nov 2027
siRNA to lower tauPossible
Arrowhead's ARO-MAPT, an injection that lowers tau production, is in early trials (160 people, due June 2027).
-
3 years
by late 2029
Restoring brain cell energyLong shot
NADAPT (330 people) tests nicotinamide riboside, a vitamin B3 form; due December 2028.
Testing several drugs at oncePossible
The PSP Trial Platform (440 people) tests the AADvac1 tau vaccine and LM11A-31 against a shared placebo; due September 2030.
-
5 years
by late 2031
The first phase 3 of a tau-lowering drugPossible 80.41% less free tau (bepranemab)
Novartis' NIO752, an antisense drug injected into the spinal fluid to reduce tau production, is in phase 3 (300 people, due July 2029).
80.41%: reduction in free tau in spinal fluid.
The research paths
Lowering tau production
Details and 2 trialsHide
Antisense and siRNA drugs that reduce how much tau the brain makes.
WatchNIO752 phase 3; ARO-MAPT.
Targeting tau protein
80.41% less free tauDetails and 3 trialsHide
Antibodies, vaccines and pills that clear tau or stop it clumping.
WatchPROSPER; PSP Trial Platform.
- FNP-223, an O-GlcNAcase inhibitor (PROSPER)Ferrer · 241 people · fully enrolled Nov 2026
- PSP Trial Platform (AADvac1 vaccine, LM11A-31)University of California, San Francisco (Adam Boxer) · 440 people · enrolling Sep 2030
- PSP Platform regimen A: AADvac1 tau vaccineUniversity of California, San Francisco (Adam Boxer) · 146 people · enrolling Sep 2030
Protecting brain cells
Details and 3 trialsHide
Energy, progranulin and nerve-growth approaches; several failures so far.
WatchNADAPT; LM11A-31.
- Nicotinamide riboside (NADAPT)Haukeland University Hospital · 330 people · enrolling Dec 2028
- PSP Platform regimen B: LM11A-31University of California, San Francisco (Adam Boxer) · 147 people · enrolling Sep 2030
- Tributyrin (virtual trial)University of Michigan (Prabesh Kanel) · 15 people · enrolling May 2027
Borrowed from other conditions
From Alzheimer's disease research
Tau antisense and siRNA
Phase 3
Tau-lowering drugs also being tested in Alzheimer's disease.
From Parkinson disease research
Nicotinamide riboside
Phase 2
A vitamin B3 form tested to support brain cell energy.
From ALS
AMX0035
Stopped
Tested in PSP after ALS; withdrawn from the ALS market in 2024.
Open to join now
-
PSP
NIO752
Locations and eligibility → -
PSP
PSP Trial Platform
Locations and eligibility → -
Early Alzheimer disease and PSP
ARO-MAPT-SC
Locations and eligibility → -
PSP
Nicotinamide riboside
Locations and eligibility →
See every recruiting PSP trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Progranulin drug safe, with early signals
AZP2006, Movement Disorders.
AMX0035 trial stopped for lack of benefit
ORION.
Standard treatment today
- DiagnosisClinical exam (eye movement, falls), MRI; tau PET in research.
- EarlyTrial of levodopa (helps a minority); physical therapy to reduce falls; clinical trials.
- ProgressingSpeech and swallowing therapy, eye care, home safety, mobility aids.
- AdvancedSupportive and palliative care; feeding decisions.
How to read this page, and sourcesHow to read this page, and sources
- Biomarker changes (such as lower tau) do not yet prove a drug slows PSP.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See PSP trials recruiting now →